




Sales (ex pm) – £3,846m




Underlying Operating Profit - £525m



Truly global group with increasing emerging market exposure




Strong bottom line rewards shareholders



Our strategy will deliver sustained growth and value creation

- Driving attractive returns:**
- Expanding ROIC to 20%
 - Mid to high single digit EPS CAGR
 - Progressive dividend policy

Clean Air




- A global leader providing catalysts to reduce harmful emissions from vehicles
 - Light Duty Vehicles** - catalysts for cars and other light duty vehicles powered by all fuel types
 - Heavy Duty Diesel** - catalyst systems for diesel powered trucks and buses and non road machinery
 - Other** - catalyst systems for stationary equipment
- Margin: 14.2%
 - Return on invested capital: 30.8%
 - Employees: 5,470

Our strategy will deliver:
Mid single digit sales CAGR over the next decade

Sustained growth

Efficient Natural Resources




- Catalyst Technologies** - manufactures speciality catalysts and additives, licenses process technology and delivers services to the chemical and oil & gas industry
 - PGM Services** - marketing, distribution, refining and recycling of platinum group metals (pgms), fabricates products using precious metals and related materials and manufactures pgm chemicals
 - Advanced Glass Technologies** - precious metal pastes and enamels primarily for the automotive industry
- Margin: 16.5%
 - Return on invested capital: 12.0%
 - Employees: 3,711

Our strategy will deliver:
Sales growth at 1% above the market (excluding PGMS) and operating profit at 1% above sales growth

Market leading growth

Health




- Develops and manufactures active pharmaceutical ingredients (APIs) for a variety of treatments
 - Operates in the large and growing outsourced small molecule API market
 - Providing solutions to the complex problems of both generic and innovator companies
- Margin: 18.0%
 - Return on invested capital: 8.4%
 - Employees: 964

Our strategy will deliver:
Double digit sales growth from 2019/20 with margin reaching the high 20%^s

Break out growth

New Markets



- Alternative Powertrain** – provides battery materials for automotive applications, battery systems for a range of applications and fuel cell technologies
 - Medical Device Components** - leverages our science and technology to develop products found in devices used in medical procedures
 - Life Science Technologies** - provides advanced catalysts and processes to the pharmaceutical and agricultural chemicals markets
- Margin: 5.3%
 - Return on invested capital: 8.1%
 - Employees: 1,714

Our strategy for development of battery materials expects our eLNO material to be in commercial production from 2021/22

Break out growth in Battery Materials

All numbers based on full year 2017/18

Cautionary statement: This factsheet contains forward looking statements that are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which Johnson Matthey operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated.